PER1 and breast cancer: Employing the previously selected CpGs, PER1 showed a significant higher methylation level in breast cancer patients (mean of 2.58% in benign controls versus 2.87% in breast cancer cases, p = 0.0172) and early invasive breast cancer patients (2.6% versus 2.98%, p = 0.0058).